Today, The Zacks Investment Research lowers the Stock rating of Karyopharm Therapeutics Inc. (KPTI)

Today, The Zacks Investment Research lowers the Stock rating of Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

KPTI has been the subject of a number of other research reports. Jefferies Group raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the company from $9.00 to $12.00 in a report on Tuesday, August 30th. Robert W. Baird reissued a “positive” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, September 6th. Wedbush reissued an “outperform” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, August 4th. HC Wainwright reissued a “buy” rating on shares of Karyopharm Therapeutics in a report on Tuesday, November 8th. Finally, Vetr raised Karyopharm Therapeutics from a “hold” rating to a “strong-buy” rating and set a $11.00 target price for the company in a report on Tuesday, September 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average target price of $15.47.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 10.01 on Friday. The stock’s market cap is $412.84 million. Karyopharm Therapeutics has a 12-month low of $4.83 and a 12-month high of $19.41. The company’s 50-day moving average price is $8.76 and its 200-day moving average price is $8.33.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, November 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.12. On average, equities analysts expect that Karyopharm Therapeutics will post ($3.00) EPS for the current fiscal year.

In related news, insider Ran Frenkel sold 3,309 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $10.06, for a total value of $33,288.54. Following the completion of the transaction, the insider now directly owns 14,691 shares in the company, valued at $147,791.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.79% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Advisors LLC raised its position in shares of Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock valued at $111,000 after buying an additional 1,498 shares during the last quarter. Emerald Acquisition Ltd. raised its position in Karyopharm Therapeutics by 46.2% in the third quarter. Emerald Acquisition Ltd. now owns 14,327 shares of the company’s stock valued at $139,000 after buying an additional 4,527 shares in the last quarter. Endurance Wealth Management Inc. raised its position in Karyopharm Therapeutics by 166.7% in the third quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock valued at $156,000 after buying an additional 10,000 shares in the last quarter. Bank of Montreal Can purchased a new position in Karyopharm Therapeutics during the third quarter valued at approximately $159,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Karyopharm Therapeutics during the third quarter valued at approximately $162,000. Institutional investors own 49.20% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Related posts

Leave a Comment